A detailed history of Vestmark Advisory Solutions, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Vestmark Advisory Solutions, Inc. holds 328,246 shares of NTLA stock, worth $4.81 Million. This represents 0.28% of its overall portfolio holdings.

Number of Shares
328,246
Previous 355,325 7.62%
Holding current value
$4.81 Million
Previous $7.95 Million 15.18%
% of portfolio
0.28%
Previous 0.36%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$19.72 - $27.36 $533,997 - $740,881
-27,079 Reduced 7.62%
328,246 $6.75 Million
Q2 2024

Aug 12, 2024

SELL
$20.02 - $27.22 $1.3 Million - $1.77 Million
-65,072 Reduced 15.48%
355,325 $7.95 Million
Q1 2024

May 15, 2024

BUY
$23.82 - $32.8 $3.68 Million - $5.06 Million
154,416 Added 58.06%
420,397 $11.6 Million
Q4 2023

Feb 06, 2024

BUY
$23.16 - $32.34 $6.16 Million - $8.6 Million
265,981 New
265,981 $8.11 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.11B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Vestmark Advisory Solutions, Inc. Portfolio

Follow Vestmark Advisory Solutions, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestmark Advisory Solutions, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vestmark Advisory Solutions, Inc. with notifications on news.